Invention Grant
- Patent Title: Oncolytic adenoviruses coding for bi-specific antibodies
-
Application No.: US15559080Application Date: 2016-03-17
-
Publication No.: US11485791B2Publication Date: 2022-11-01
- Inventor: Akseli Hemminki , Suvi Parviainen , Siri Tähtinen , Ilkka Liikanen , Mikko Siurala
- Applicant: TILT Biotherapeutics Oy
- Applicant Address: FI Helsinki
- Assignee: TILT Biotherapeutics Oy
- Current Assignee: TILT Biotherapeutics Oy
- Current Assignee Address: FI Helsinki
- Agency: Laine IP Oy
- Agent Mark W. Scott
- Priority: FI20155182 20150317
- International Application: PCT/FI2016/050164 WO 20160317
- International Announcement: WO2016/146894 WO 20160922
- Main IPC: C12N15/86
- IPC: C12N15/86 ; C07K16/30 ; C07K16/28 ; A61K39/00
Abstract:
The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to an oncolytic adenoviral vector encoding a bispecific monoclonal antibody. Furthermore, the present invention relates to methods and uses utilizing the oncolytic adenoviral vectors, also together with adoptive cell therapies.
Public/Granted literature
- US20180072809A1 Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto Public/Granted day:2018-03-15
Information query
IPC分类:
